Cardiovascular Agents --pharmacokineticsDasgupta, AsishDastidar, Sujata G2012-08-142012-08-142012-06Dasgupta Asish, Dastidar Sujata G. Antibacterial & antitoxic effects of the cardiovascular drug lacidipine in an animal model. Indian Journal of Medical Research. 2012 Jun; 135(6): 913-916.http://imsear.searo.who.int/handle/123456789/140338Background & objectives: Vibrio cholerae produces acute infection by liberating potent enterotoxin, called cholera toxin in human intestine. Cardiovascular drug lacidipine possessing powerful in vitro action against V. cholerae was tested to determine its possible activity against a toxigenic V. cholerae strain in an established animal model. Methods: In the rabbit intestine four loops were constructed, 3 of which were injected with over night grown V. cholerae 569B culture. Of these, two loops were simultaneously given graded doses (100, 200 μg) of lacidipine, one was left as such for a positive control. The first loop received sterile medium (negative control). After 18 h, contents of all the loops were examined for accumulation of fluid and number of viable cells. Results: Lacidipine when administrated with live V. cholerae 569B, caused a reduction in the number of viable bacteria along with amount of fluid in the loops. The amount of fluid and number of viable cells were much reduced in the loop that had 200 μg of lacidipine than the loop that received 100 μg of the drug. Interpretation & conclusions: Lacidipine has distinct inhibitory action against V. cholerae 569B with respect to both viability and production of cholera toxin in the rabbit ileum. Structural modifications of this compound may possibly lead to procurement of new potent antimicrobial drugs.enAntibacterialantitoxigeniccholera toxinlacidipinenon-antibioticVibrio choleraeDisease Models, AnimalCardiovascular AgentsDihydropyridines --therapeutic useRabbitsVibrio cholerae --drug effectsArticle